Opinion: The Barrier to ALS Precision Drugs Isn’t Science. It’s the ‘Valley of Death’

As Congress debates renewing the Act for ALS, it must prepare for the coming era of precision ALS medicine by prioritizing early-stage research to more quickly bring effective treatments to the market.